EVOTEC (ETR:EVT) target price raised to 5.40EUR, reported today by Bankhaus Lampe KG
- Updated: October 4, 2016
EVOTEC (ETR:EVT) had its target price raised to 5.40EUR by Bankhaus Lampe KG in a report released 10/04/2016. The new target price indicates a possible upside of 0.06% based on the company's last closing price.
Previously on Monday October 03, 2016, Oddo Seydler Bank AG reported on EVOTEC (ETR:EVT) raised the target price from 0.00EUR to 5.60EUR. At the time, this indicated a possible upside of 0.12%.
Yesterday EVOTEC (ETR:EVT) traded -0.99% lower at 5.10EUR. The company’s 50-day moving average is 20.58EUR and its 200-day moving average is 20.22EUR. The last closing price is down -0.95% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 127,115 shares of the stock were exchanged, down from an average trading volume of 129,295
With a total market value of 0 EUR, EVOTEC has with a one year low of 16.37EUR and a one year high of 21.25EUR .
Brief Synopsis About EVOTEC (ETR:EVT)
Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator's targets and programs. EVT Innovate focuses on developing its internal assets, including early-stage discovery programs, as well as drug candidates. The Company focuses on therapeutic areas, including central nervous system (CNS)/neurology, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. Its clinical products include EVT302, EVT201, EVT100 and EVT401. Its pre-clinical products include EVT770, EVT801, EVT701 and EVT601. EVT302 is an inhibitor of monoamine oxidase type B (MAO-B), an enzyme that breaks down the chemical messenger dopamine in the brain and contributes to the production of free radicals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.